Skip to main content

Table 3 Outlets with specific anti-malarial categories as a percentage of outlets with at least one anti-malarial in stock, by sector¹

From: Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries

  Benin DRC Madagascar Nigeria Uganda Zambia
  Public/Not- for-Profit Private Public/Not- for-Profit Private Public/Not- for-Profit Private Public/Not- for-Profit Private Public/Not- for-Profit Private Public/Not- for-Profit Private
  N=212 N=632 N=134 N=1, 240 N=560 N=1, 854 N=249 N=1, 864 N=534 N=691 N=176 N=259
Any ACT 71.4 a 6.4 b 84.4 a 52.7 b 92.2 a 8.4 b 60.6 a 36.7 a 81.5 a 20.1 b 82.2 a 19.3 b
   First-line quality-assured ACT 66.4 a 5.7 b 75.8 a 24.5 b 91.9 a 7.9 b 49.2 a 25.3 b 73.4 a 7.8 b 81.5 a 16.3 b
   Quality-assured ACT 66.4 a 5.9 b 78.7 a 29.0 b 91.9 a 8.1 b 49.2 a 26.1 a 73.4 a 8.1 b 81.5 a 16.3 b
   Non-Quality-assured ACT 5.1 a 0.5 b 5.6 a 23.6 b 0.3 a 0.3 a 11.5 a 10.5 a 9.3 a 15.2 a 0.8 a 2.9 b
Any non-artemisinin therapy 96.7 a 99.7 b 93.8 a 97.8 a 36.3 a 99.3 b 81.7 a 98.2 b 68.6 a 99.6 b 98.4 a 98.8 a
   Chloroquine 9.3 a 82.1 b 0.0 a 4.0 b 1.6 a 95.5 b 57.7 a 91.9 b 15.5 a 61.0 b 0.0 a 21.7 b
   SP 51.2 a 15.8 b 66.9 a 57.9 a 22.0 a 9.2 a 62.7 a 78.3 a 49.9 a 68.2 a 65.5 a 80.2 a
   Quinine 92.5 a 24.0 b 85.7 a 84.3 a 23.3 a 10.7 a 20.0 a 9.2 a 59.0 a 82.9 b 89.1 a 16.8 b
   Quinine injection 60.0 a 8.0 b 65.6 a 40.7 b 20.9 a 9.5 a 19.0 a 0.6 b 56.4 a 32.6 a 51.2 a 8.7 b
Oral artemisinin monotherapy 3.8 a 0.7 a 10.2 a 40.5 b 0.0 a < 0.1 a 4.1 a 45.1 b 1.3 a 13.3 b 1.1 a 2.5 a
  1. ¹Statistical comparisons conducted across outlet types, within countries. Statistical difference is labelled with a superscript, a or b. Proportions with different letters in their superscripts differ significantly from one another within countries (p < 0.05 for all tests).